DM1-SMe

DM1-SMe is an unconjugated form of the Maytansinoid in IMGN901. DM1-SMe is the microtubule inhibitor and can be used as the ADC cytotoxin[1].

Product Specifications

CAS Number

[138148-68-2]

UNSPSC

12352203

Hazard Statement

H303, H312, H315, H317, H319, H335, H336, H351, H361, H372, H412

Target

ADC Payload; Microtubule/Tubulin

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/dm1-sme.html

Purity

99.08

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C[C@]12[C@@]([C@@H]([C@]3([H])C[C@]([C@@H](/C=C/C=C(CC4=CC(N(C(C[C@@H]2OC([C@H](C)N(C)C(CCSSC)=O)=O)=O)C)=C(C(OC)=C4)Cl)\C)OC)(NC(O3)=O)O)C)([H])O1

Molecular Formula

C36H50ClN3O10S2

Molecular Weight

784.38

Precautions

H303, H312, H315, H317, H319, H335, H336, H351, H361, H372, H412

References & Citations

[1]Wood AC, et al. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013;60 (11) :1860-1867. |[2]Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41 (1) :98-107.